- Home
- MOLN vs GNLX Comparison
MOLN vs GNLX Comparison
Compare MOLN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- GNLX
- Stock Information
- Founded
- MOLN 2004
- GNLX 2001
- Country
- MOLN Switzerland
- GNLX United States
- Employees
- MOLN N/A
- GNLX N/A
- Industry
- MOLN
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- GNLX Health Care
- Exchange
- MOLN Nasdaq
- GNLX Nasdaq
- Market Cap
- MOLN 183.2M
- GNLX 184.4M
- IPO Year
- MOLN 2021
- GNLX 2023
- Fundamental
- Price
- MOLN $4.10
- GNLX $2.96
- Analyst Decision
- MOLN
- GNLX Strong Buy
- Analyst Count
- MOLN 0
- GNLX 4
- Target Price
- MOLN N/A
- GNLX $17.75
- AVG Volume (30 Days)
- MOLN 25.8K
- GNLX 138.3K
- Earning Date
- MOLN 03-06-2025
- GNLX 05-06-2025
- Dividend Yield
- MOLN N/A
- GNLX N/A
- EPS Growth
- MOLN N/A
- GNLX N/A
- EPS
- MOLN N/A
- GNLX N/A
- Revenue
- MOLN $5,484,562.00
- GNLX N/A
- Revenue This Year
- MOLN N/A
- GNLX N/A
- Revenue Next Year
- MOLN $866.67
- GNLX N/A
- P/E Ratio
- MOLN N/A
- GNLX N/A
- Revenue Growth
- MOLN N/A
- GNLX N/A
- 52 Week Low
- MOLN $3.36
- GNLX $1.60
- 52 Week High
- MOLN $12.70
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MOLN 52.08
- GNLX 54.28
- Support Level
- MOLN $3.79
- GNLX $2.26
- Resistance Level
- MOLN $4.27
- GNLX $3.06
- Average True Range (ATR)
- MOLN 0.27
- GNLX 0.31
- MACD
- MOLN 0.04
- GNLX 0.04
- Stochastic Oscillator
- MOLN 66.07
- GNLX 78.42
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.